Biosimilars and next-gen therapies will impact Crohn's disease market

There is a transformative shift taking place in the Crohn's disease (CD) treatment market, challenging AbbVie's (NYSE: ABBV) mega blockbuster biological Humira's (adalimumab) long-standing dominance. Humira is still notching up sales of over $20 billion a year globally for all its approved indications

Adalimumab biosimilars are reshaping the landscape, impacting Humira and competitors such as Johnson & Johnson (NYSE: JNJ)/Janssen's Stelara (ustekinumab) and Takeda's (TYO: 4502) Entyvio (vedolizumab). With a focus on biologic-exposed CD patients, novel therapies for TNF-refractory individuals are gaining prominence. Advancements in biologics and oral small molecules are driving dynamic changes, potentially altering the market hierarchy, says GlobalData, a leading data and analytics company.

GlobalData’s estimates that over the last five years, AbbVie has remained the market leader within CD, with Humira sales in this indication alone of $2.7 billion in 2022 in the eight major markets ((8MM; the USA, Canada, UK, France, Germany, Spain, Italy and Japan).